UA100967C2 - Конъюгаты нейбластина с полимерами и способы их применения - Google Patents

Конъюгаты нейбластина с полимерами и способы их применения

Info

Publication number
UA100967C2
UA100967C2 UAA200802148A UAA200802148A UA100967C2 UA 100967 C2 UA100967 C2 UA 100967C2 UA A200802148 A UAA200802148 A UA A200802148A UA A200802148 A UAA200802148 A UA A200802148A UA 100967 C2 UA100967 C2 UA 100967C2
Authority
UA
Ukraine
Prior art keywords
heading
neublastin
normal
methods
same
Prior art date
Application number
UAA200802148A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дінах В. У. Сах
Р. Блейк Пепінскі
Паула Енн Борджек-С'єдін
Стефан С. Міллєр
Ентоні Россомандо
Original Assignee
Байоджен Айдек Ма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Інк. filed Critical Байоджен Айдек Ма Інк.
Publication of UA100967C2 publication Critical patent/UA100967C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Изобретение относится к полипептиду нейбластина, пригодному для образования конъюгата, содержащему полипептид нейбластина, связанный с полиалкиленгликолем. Данный конъюгат имеет пролонгированную биологическую активность по сравнению с немодифицированными формами или формами дикого типа нейбластина. Конъюгаты согласно изобретению применяют при лечении или профилактике заболевания или расстройства нервной системы.
UAA200802148A 2001-02-01 2002-01-25 Конъюгаты нейбластина с полимерами и способы их применения UA100967C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
UA100967C2 true UA100967C2 (ru) 2013-02-25

Family

ID=23013042

Family Applications (2)

Application Number Title Priority Date Filing Date
UA2003088104A UA82983C2 (ru) 2001-02-01 2002-01-25 Полимерные коньюгаты найбластина и способы их использования
UAA200802148A UA100967C2 (ru) 2001-02-01 2002-01-25 Конъюгаты нейбластина с полимерами и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA2003088104A UA82983C2 (ru) 2001-02-01 2002-01-25 Полимерные коньюгаты найбластина и способы их использования

Country Status (36)

Country Link
EP (2) EP1355936B1 (ru)
JP (2) JP4259868B2 (ru)
KR (2) KR100960063B1 (ru)
CN (1) CN1500095B (ru)
AR (1) AR035077A1 (ru)
AT (1) ATE365748T1 (ru)
AU (1) AU2002247037B2 (ru)
BG (1) BG66393B1 (ru)
BR (1) BR0206852A (ru)
CA (1) CA2436407C (ru)
CY (1) CY1106886T1 (ru)
CZ (1) CZ20032080A3 (ru)
DE (1) DE60220879T2 (ru)
DK (1) DK1355936T3 (ru)
EA (1) EA009771B1 (ru)
EE (1) EE05537B1 (ru)
ES (1) ES2289091T3 (ru)
GE (1) GEP20063916B (ru)
HK (1) HK1057759A1 (ru)
HU (1) HU228973B1 (ru)
IL (2) IL156941A0 (ru)
IS (1) IS2867B (ru)
MX (1) MXPA03006805A (ru)
MY (1) MY143685A (ru)
NO (1) NO332150B1 (ru)
NZ (1) NZ527863A (ru)
PL (1) PL211162B1 (ru)
PT (1) PT1355936E (ru)
RS (1) RS50857B (ru)
SG (1) SG149685A1 (ru)
SI (1) SI1355936T1 (ru)
SK (1) SK288123B6 (ru)
TR (1) TR200301208T2 (ru)
UA (2) UA82983C2 (ru)
WO (1) WO2002060929A2 (ru)
ZA (1) ZA200305733B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
SI1355936T1 (sl) * 2001-02-01 2007-12-31 Biogen Idec Inc Polimerni konjugati neublastina in postopki njihove uporabe
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ATE526982T1 (de) * 2001-03-28 2011-10-15 Biogen Idec Inc Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
BRPI0306993B8 (pt) * 2002-01-18 2021-05-25 Biogen Idec Inc polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
NZ541921A (en) 2003-01-31 2010-01-29 Biogen Idec Inc Polymer conjugates of mutated neublastin
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
EP1784203B1 (en) * 2004-08-19 2010-06-30 Biogen Idec MA Inc. Refolding transforming growth factor beta family proteins
EP2238983B1 (en) 2004-08-19 2014-07-23 Biogen Idec MA Inc. Neublastin variants
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
PL2068935T3 (pl) 2006-09-15 2011-11-30 Creabilis Therapeutics S R L Polimerowe koniugaty BOX-A HMGB1 i warianty HMGB1
EP2142205B1 (en) * 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
CN104023804B (zh) * 2011-11-02 2017-05-24 弗·哈夫曼-拉罗切有限公司 超载和洗脱层析
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
SI1355936T1 (sl) * 2001-02-01 2007-12-31 Biogen Idec Inc Polimerni konjugati neublastina in postopki njihove uporabe

Also Published As

Publication number Publication date
NZ527863A (en) 2006-09-29
AU2002247037B2 (en) 2007-08-16
AR035077A1 (es) 2004-04-14
ATE365748T1 (de) 2007-07-15
HUP0500637A2 (hu) 2005-09-28
IS6879A (is) 2003-07-17
KR20080098662A (ko) 2008-11-11
EP1355936B1 (en) 2007-06-27
SG149685A1 (en) 2009-02-27
DK1355936T3 (da) 2007-10-29
KR100872807B1 (ko) 2008-12-09
CA2436407C (en) 2011-08-30
WO2002060929A3 (en) 2003-03-06
WO2002060929A2 (en) 2002-08-08
PL211162B1 (pl) 2012-04-30
ZA200305733B (en) 2005-02-23
BR0206852A (pt) 2005-05-03
KR20030074766A (ko) 2003-09-19
SK9712003A3 (en) 2004-01-08
CN1500095A (zh) 2004-05-26
PL372101A1 (en) 2005-07-11
YU61003A (sh) 2006-05-25
MXPA03006805A (es) 2003-11-13
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
IS2867B (is) 2014-02-15
DE60220879T2 (de) 2008-03-06
NO332150B1 (no) 2012-07-09
JP4423338B2 (ja) 2010-03-03
MY143685A (en) 2011-06-30
KR100960063B1 (ko) 2010-05-31
JP2005503763A (ja) 2005-02-10
HK1057759A1 (en) 2004-04-16
BG108111A (bg) 2004-12-30
EA200300852A1 (ru) 2004-06-24
ES2289091T3 (es) 2008-02-01
SK288123B6 (sk) 2013-09-03
NO20033441D0 (no) 2003-08-01
EP1355936A2 (en) 2003-10-29
HU228973B1 (en) 2013-07-29
HUP0500637A3 (en) 2010-01-28
PT1355936E (pt) 2007-09-28
GEP20063916B (en) 2006-09-11
NO20033441L (no) 2003-10-01
CY1106886T1 (el) 2012-09-26
BG66393B1 (bg) 2013-11-29
IL156941A (en) 2008-11-03
UA82983C2 (ru) 2008-06-10
CA2436407A1 (en) 2002-08-08
CN1500095B (zh) 2010-06-16
EE05537B1 (et) 2012-04-16
JP4259868B2 (ja) 2009-04-30
SI1355936T1 (sl) 2007-12-31
EA009771B1 (ru) 2008-04-28
EE200300355A (et) 2003-10-15
RS50857B (sr) 2010-08-31
IL156941A0 (en) 2004-02-08
DE60220879D1 (de) 2007-08-09
CZ20032080A3 (cs) 2003-10-15
TR200301208T2 (tr) 2005-05-23

Similar Documents

Publication Publication Date Title
UA100967C2 (ru) Конъюгаты нейбластина с полимерами и способы их применения
EP1196444B8 (en) Exendin-4 conjugates and their medical use
AU7761594A (en) Polyethylene glycols
WO2001051510A3 (en) G-csf conjugates
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
MXPA05002814A (es) Formulacion para agentes lipofilicos.
BR9917007A (pt) Moduladores de ccr5
NO20011860L (no) Polymerkonjugater av interferon <beta>-1A samt anvendelse derav
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
UY27373A1 (es) Formulaciones de interferón beta-humano
AU2002700A (en) Novel depsipeptide compound
AU3739500A (en) Protease resistant flint analogs
EP1947109A3 (en) Biologically active peptides
MXPA02008012A (es) Derivados de 9-alquilamino-1-nitroacridina.